Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 1.Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma

EP: 2.Understanding the Role of BCMA-Targeted CAR-T Therapies in R/R MM

EP: 3.KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MM

EP: 4.CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MM

EP: 5.Optimizing BCMA-Targeted CAR-T Therapies: Patient Selection, Clinical Impact, and Treatment Sequencing

EP: 6.BCMA-Targeted CAR-T Therapies in Development and Future Perspective

This is a video synopsis/summary of an OncLive® Post-Conference Perspectives involving Rafat Abonour, MD, and Noopur Raje, MD.

The video begins with Abonour welcoming viewers to the program on bispecific T-cell engager (BiTE) and chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma. He introduces his cohost, Raje, director of the Center for Multiple Myeloma at Massachusetts General Hospital and professor at Harvard Medical School.

Abonour notes that 2½ years ago, treatment options for relapsed/refractory multiple myeloma were limited, with low response rates and low overall survival rates. However, therapies targeting B-cell maturation antigen (BCMA) expressed on myeloma cells, including BiTEs and CAR T cells, have led to dramatic improvements. Now overall response rates exceed 90%, with deep responses and minimal residual disease–negative bone marrow achieved quickly after treatment. PET scans that previously showed widespread disease are now coming back negative after these BCMA-targeted treatments.

With this background, Abonour concludes the introductory segment, indicating they will next discuss advances presented at the 2023 American Society of Hematology Annual Meeting and Exposition.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.